全球胃轻瘫市场:各地区与国家分析与预测(2025-2035)
市场调查报告书
商品编码
1759273

全球胃轻瘫市场:各地区与国家分析与预测(2025-2035)

Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

胃轻瘫市场的主要成长要素之一是第1型和第2型糖尿病盛行率的上升。糖尿病是糖尿病性胃轻瘫的主要原因之一,这种疾病是由于高血糖损害控制胃部肌肉的迷走神经而发生的。这种神经损伤会导致排放延迟,这是胃轻瘫的典型症状。随着糖尿病患者人数的增加,尤其是在开发中国家,糖尿病性胃轻瘫的发生率也在上升,这推动了对该疾病治疗和管理的需求。

此外,血糖控制不佳的糖尿病患者数量不断增加,需要创新的解决方案来解决胃轻瘫的併发症,如噁心、呕吐、早饱、血糖值难以预测等。患者数量的不断增长,以及胃电刺激设备和胃肠动力预防等先进诊断和治疗方法的发展,正在推动市场成长。

儘管胃轻瘫市场正在成长,但仍存在一些挑战阻碍其发展。其中最主要的挑战之一是缺乏早期诊断或漏诊。胃轻瘫常与其他消化系统疾病(例如大肠激躁症(IBS) 和胃食道逆流症 (GERD))重迭,且症状特异性,导致误诊和延迟诊断。

诊断本身很复杂,需要进行胃排空排放显像、呼吸检测和上消化道内视镜等专门检查,而并非所有医疗机构都提供这些检查。由于缺乏标准化的检查,且先进诊断设备的使用受限,诊断常常被延误,直至病情发展到严重阶段,从而导致治疗困难。

此外,治疗方案有限。目前使用的胃肠促动力药物和胃电刺激设备并非对所有患者都有效,副作用也可能限制其使用。我们有必要发展针对潜在病因的治疗方法,尤其是针对糖尿病性胃轻瘫等潜在疾病。

此外,长期管理、专门治疗和反覆就诊相关的高昂医疗费用给患者和医疗保健系统带来了沉重的负担,阻碍了患者获得治疗的机会和接受治疗,特别是在资源有限的地区,并且儘管对更有效的治疗方法有需求,但仍阻碍了市场增长。

本报告调查了全球胃轻瘫市场,并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

第一章全球胃轻瘫市场:产业展望

  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 全球胃轻瘫市场(按地区)

  • 北美洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 欧洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

3. 全球胃轻瘫市场:竞争格局与公司概况

  • 主要策略和发展
    • M&A
    • 协同活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Vanda Pharmaceuticals
    • Processa Pharmaceuticals
    • Neurogastrx
    • CinDome Pharma
    • Evoke Pharma
    • AbbVie Inc.
    • AstraZeneca
    • Boehringer Ingelheim
    • Ironwood Pharmaceuticals

第四章调查方法

Product Code: BHL3071SA

Global Gastroparesis Market, Analysis and Forecast: 2025-2035

Gastroparesis is a gastrointestinal disorder characterized by delayed gastric emptying, where the stomach takes too long to empty its contents, despite the absence of any physical obstruction in the stomach or intestines. This condition is typically caused by nerve damage, particularly to the vagus nerve, which plays a critical role in controlling the stomach and intestinal muscles. When the vagus nerve is damaged, it disrupts the normal motility (movement) of the stomach, resulting in difficulty effectively emptying the stomach. Symptoms of gastroparesis include nausea, vomiting (especially after meals), bloating, early satiety, abdominal pain, loss of appetite, weight loss, heartburn, and unpredictable blood sugar levels, particularly in diabetic patients.

Common causes of the condition include diabetes, where elevated blood sugar levels damage the vagus nerve, idiopathic gastroparesis (where the cause remains unknown), and post-surgical gastroparesis following stomach or esophageal surgery. Neurological conditions like Parkinson's disease and multiple sclerosis can also lead to gastroparesis, as well as the use of certain medications such as opioids. Diagnosis typically involves gastric emptying scintigraphy, breath tests, and imaging techniques like upper endoscopy or ultrasound to rule out other potential conditions.

Treatment for gastroparesis aims to alleviate symptoms and improve gastric motility, and may include dietary modifications, medications like prokinetic agents (e.g., metoclopramide), antiemetics to control nausea, gastric electrical stimulation (GES) devices, or surgical interventions like pyloroplasty in severe cases. While gastroparesis can significantly impact a person's quality of life, proper management strategies enable most patients to control symptoms and improve their ability to eat and absorb nutrients.

One of the key drivers of the Gastroparesis market is the increasing prevalence of diabetes, particularly type 1 and type 2 diabetes. Diabetes is one of the primary causes of diabetic gastroparesis, a condition that occurs when high blood sugar levels damage the vagus nerve, which controls the muscles of the stomach. This nerve damage leads to delayed gastric emptying, a hallmark symptom of gastroparesis. As the global rates of diabetes continue to rise, particularly in developing countries, the incidence of diabetic gastroparesis increases, thereby driving the demand for effective treatments and therapies to manage the condition.

Additionally, the growing number of individuals with poorly controlled diabetes has increased the need for innovative solutions to manage the complications associated with gastroparesis, such as nausea, vomiting, early satiety, and unpredictable blood sugar levels. This growing patient population, combined with the development of advanced diagnostic tools and therapeutic options like gastric electrical stimulators and prokinetic agents, is fuelling the growth of the gastroparesis market.

Despite the growth of the Gastroparesis market, several challenges continue to hinder its progress. One of the primary challenges is the lack of early diagnosis and underdiagnosis of the condition. Gastroparesis often presents with symptoms that are non-specific and overlap with other gastrointestinal disorders, such as irritable bowel syndrome (IBS), acid reflux, or gastroesophageal reflux disease (GERD). As a result, many patients are misdiagnosed or experience delays in receiving the correct diagnosis.

The diagnostic process itself can be complex and involves specialized tests like gastric emptying scintigraphy, breath tests, and upper endoscopy, which may not always be readily available in all healthcare settings. This lack of standardization in testing and limited access to advanced diagnostics means that gastroparesis is often diagnosed only after significant symptoms develop, complicating treatment.

Additionally, the treatment landscape for gastroparesis remains somewhat limited. While there are treatments available, such as prokinetic agents and gastric electrical stimulators, these options are not always effective for all patients, and side effects can limit their use. The need for more targeted therapies that address the underlying causes of gastroparesis especially in cases like diabetic gastroparesis remains an ongoing challenge in the market.

Furthermore, high healthcare costs associated with long-term management, specialized treatments, and recurrent hospital visits place an additional burden on both healthcare systems and patients, especially in regions with limited resources. These challenges hinder the overall accessibility and adoption of existing treatments, despite the growing demand for more effective solutions.

The global Gastroparesis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, and Neurogastrx are at the forefront, developing novel treatments like VLY-686 (Tradipitant), PC1050, and NGX-4010 that target the underlying causes of gastric motility disorders in gastroparesis.

Other notable players, including CinDome Pharma and Evoke Pharma, are advancing treatment options with therapies like CIN-102 (deudomperidone) and Gimoti (metoclopramide nasal spray), offering more effective and convenient delivery systems for managing nausea and vomiting in gastroparesis patients.

Large pharmaceutical companies such as AbbVie, AstraZeneca, and Boehringer Ingelheim are also contributing to the market by expanding their portfolios with therapies that aim to improve gastric motility and alleviate symptoms associated with gastroparesis. With a focus on innovation, these companies are continuously pushing the boundaries of research and development to provide better treatment options, improve patient quality of life, and capture a larger share of the growing Gastroparesis market.

Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Gastroparesis market is undergoing significant transformation, fueled by several key factors that are reshaping the landscape of treatment and care. One of the primary drivers is the rising prevalence of diabetes, particularly type 1 and type 2 diabetes, which is one of the leading causes of diabetic gastroparesis. As the incidence of diabetes continues to grow worldwide, so does the demand for more effective and innovative treatments to manage the related complications, including gastroparesis. In parallel, advancements in diagnostic technologies, such as more accurate and accessible gastric emptying scintigraphy and breath tests, are enabling earlier and more accurate diagnoses, allowing for earlier intervention and better patient outcomes.

Furthermore, innovations in treatment options are contributing to market growth, with companies developing new drug formulations, gastric electrical stimulation devices, and biologic therapies designed to address the underlying causes of delayed gastric emptying. These treatments offer patients more targeted and personalized approaches, enhancing their effectiveness and minimizing side effects. As awareness about gastroparesis continues to increase, both among healthcare providers and patients, there is growing recognition of the condition as a treatable and manageable disease, further driving the demand for therapies. The combination of technological advances, increased research and development, and rising healthcare investments is propelling the market forward, positioning it for continued growth and evolution in the coming years.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Gastroparesis Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Gastroparesis Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Gastroparesis Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Gastroparesis Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Gastroparesis Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Gastroparesis Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Vanda Pharmaceuticals
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Processa Pharmaceuticals
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Neurogastrx
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 CinDome Pharma
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Evoke Pharma
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 AbbVie Inc.
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 AstraZeneca
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Boehringer Ingelheim
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Ironwood Pharmaceuticals
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Gastroparesis Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Gastroparesis Market Key Trends, Analysis

List of Tables

  • Table: Global Gastroparesis Market Dynamics, Impact Analysis
  • Table: Global Gastroparesis Market (by Region), $Billion, 2024-2035